2011
DOI: 10.1155/2011/954812
|View full text |Cite
|
Sign up to set email alerts
|

Non-Invasive Diagnostic and Prognostic Evaluation of Liver Cirrhosis and Portal Hypertension

Abstract: Abstract. Cirrhosis is the final stage of most of chronic liver diseases, and is almost invariably complicated by portal hypertension, which is the most important cause of morbidity and mortality in these patients. This review will focus on the non-invasive methods currently used in clinical practice for diagnosing liver cirrhosis and portal hypertension. The first-line techniques include physical examination, laboratory parameters, transient elastography and Doppler-US. More sophisticated imaging methods whic… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
55
1
9

Year Published

2013
2013
2020
2020

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 84 publications
(65 citation statements)
references
References 70 publications
0
55
1
9
Order By: Relevance
“…Slow responders and refractory patients have been described, 98,262 and non-invasive laboratory and radiological methods are now available to better monitor the fibrotic process. 157,166,193,263 Individualised modifications in conventional treatment may be beneficial, 16 and promising anti-fibrotic therapies that can supplement treatment must be evaluated and incorporated if validated. 58,59,226 Patients who are able to resolve all laboratory and histological manifestations of their disease within 6-12 months of conventional therapy have a low frequency of progressive hepatic fibrosis.…”
Section: Management Perspectivesmentioning
confidence: 99%
“…Slow responders and refractory patients have been described, 98,262 and non-invasive laboratory and radiological methods are now available to better monitor the fibrotic process. 157,166,193,263 Individualised modifications in conventional treatment may be beneficial, 16 and promising anti-fibrotic therapies that can supplement treatment must be evaluated and incorporated if validated. 58,59,226 Patients who are able to resolve all laboratory and histological manifestations of their disease within 6-12 months of conventional therapy have a low frequency of progressive hepatic fibrosis.…”
Section: Management Perspectivesmentioning
confidence: 99%
“…A transjugularis májbi-opszia csak néhány centrumban elérhető, biztonságo-sabb, jobban tolerálható és a hepaticus vénás nyomásgra-diens mérésére is alkalmas [13]. A májbiopszia korlátai miatt nőtt meg az elmúlt évti-zedekben az igény egyéb, olcsó, nem invazív, reprodukálható diagnosztikai módszerek kifejlesztésére, amelyek a máj kötőszövetes átépülésének mértékét jellemzik a korai fi brosistól a korai kompenzált cirrhosisig [16].…”
Section: Májbiopsziaunclassified
“…Aktuális szérumszintjüket kiválasz-tásuk is, az endothelialis diszfunkció, a csökkent epekivá-lasztás vagy a csökkent veseműködés is befolyásolhatja [23]. Meghatározásuk költséges [16].…”
Section: Táblázatunclassified
See 2 more Smart Citations